Are you providing any revenue growth guidance or margin guidance for FY '26?
Okay. So just to understand, when you move towards that CAGR number, which is 25%, so progressively from 18% that you achieved in FY '25, you will move towards that 25% gradually, is what you're seeing?
First question, sir, is on the differentiated products. So, differentiated products is one of the strengths of the company. Can you tell us what is the contribution of these products to FY '24 revenue and for the 1st Quarter as well?
And the second one is on the biologics. Biologics is again a big focus area for the company, and I believe you have new launches lined up. So, which are the geographies which will be meaningful from a biologics contribution perspective apart from India?